A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Neoplasms
Interventions
DRUG

Sunitinib, Pemetrexed, Cisplatin, Carboplatin

Dose finding study using Sunitinib daily by oral capsule in a continuous regimen or administered for 2 weeks out of every 3 weeks, with pemetrexed every 3 weeks or also with cisplatin 75 mg/m2 or carboplatin AUC=5 mg\*min/mL until progression or unacceptable toxicity.

Trial Locations (3)

80045

Pfizer Investigational Site, Aurora

K1H 8L6

Pfizer Investigational Site, Ottawa

H2L 4M1

Pfizer Investigational Site, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00528619 - A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter